{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:48:35Z","timestamp":1792259315038,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This Special Issue of Cancers, entitled \u201cAcute Myeloid Leukemia (AML): Updates on Diagnosis, Treatment and Management\u201d, will be a forum for stimulating discussions and thought-provoking debates, featuring cutting-edge scientific manuscripts on the most relevant topics related to the diagnosis and therapeutic advances for the management of AML [...]<\/jats:p>","DOI":"10.3390\/cancers17142387","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:12:34Z","timestamp":1752837154000},"page":"2387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-7167","authenticated-orcid":false,"given":"Francesco","family":"Lanza","sequence":"first","affiliation":[{"name":"Hematology Unit, Ravenna Hospital, University of Bologna, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-5554","authenticated-orcid":false,"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ravenna Hospital, University of Bologna, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ravenna Hospital, University of Bologna, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Figueroa","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN Recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lanza, F., and Bazarbachi, A. (2021). Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions. Cancers, 13.","DOI":"10.3390\/cancers13184698"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.27591","article-title":"Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents","volume":"100","author":"Marconi","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41375-025-02625-3","article-title":"Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax\/azacitidine for AML","volume":"39","author":"Ikoma","year":"2025","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: A randomized phase 3 trial","volume":"141","author":"Montesinos","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/bloodadvances.2024013182","article-title":"Risk-adapted MRD-directed therapy for young acute myeloid leukemia adults: 6-year update of the GIMEMA AML1310 trial","volume":"8","author":"Venditti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gottardi, M., Simonetti, G., Sperotto, A., Nappi, D., Ghelli Luserna di Ror\u00e0, A., Padella, A., Norata, A., Giannini, M.B., Musuraca, G., and Lanza, F. (2021). Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers, 13.","DOI":"10.3390\/cancers13184566"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia","volume":"43","author":"Steffen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: Mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"McCall, D., Alqahtani, S., Budak, M., Sheikh, I., Fan, A.E., Ramakrishnan, R., Nunez, C., Roth, M., Garcia, M.B., and Gibson, A. (2024). Cladribine-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience. Cancers, 16.","DOI":"10.3390\/cancers16223886"},{"key":"ref_22","first-page":"608","article-title":"Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy","volume":"110","author":"Mosna","year":"2024","journal-title":"Haematologica"},{"key":"ref_23","first-page":"543","article-title":"Is age just a number? Intensive therapy for core-binding factor acute myeloid leukemia in older adults","volume":"110","author":"George","year":"2025","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1007\/s00277-024-05632-z","article-title":"Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML","volume":"103","author":"Ge","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent","volume":"100","author":"Gangat","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lachowiez, C.A., Heiblig, M., Requena, G.A., Tavernier-Tardy, E., Dai, F., Ashango, A.B., Peters, D.T., Fang, J., Kaempf, A., and Long, N. (2025). Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study. Blood Cancer Discov., Online ahead of print.","DOI":"10.1158\/2643-3230.BCD-24-0256"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lanza, F., Rondoni, M., and Zannetti, B.A. (2023). New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders. Cancers, 15.","DOI":"10.3390\/cancers15092422"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rondoni, M., Marconi, G., Nicoletti, A., Giannini, B., Zuffa, E., Giannini, M.B., Mianulli, A., Norata, M., Monaco, F., and Zaccheo, I. (2025). Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype. Cancers, 17.","DOI":"10.3390\/cancers17071213"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: How can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.aay4319","article-title":"How to lose tumor suppression","volume":"365","author":"Lane","year":"2019","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature15251","article-title":"Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth","volume":"525","author":"Zhu","year":"2015","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2643-3230.BCD-24-0355","article-title":"Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases","volume":"6","author":"Usui","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_37","first-page":"1304","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"},{"key":"ref_38","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood.2020008212","article-title":"Natural born survivors: The inglorious TP53","volume":"136","author":"Platzbecker","year":"2020","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","article-title":"Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-018-0035-y","article-title":"Chromothripsis in acute myeloid leukemia: Biological features and impact on survival","volume":"32","author":"Fontana","year":"2018","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study","volume":"10","author":"Goldberg","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zeidner, J.D., Sallman, D.A., R\u00e9cher, C., Daver, N.G., Leung, A.Y., Hiwase, D.K., Subklewe, M., Pabst, T., Montesinos, P., and Larson, R.A. (2025). Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: The ENHANCE-2 study. Blood, Online ahead of print.","DOI":"10.1182\/blood.2024027408"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/10428194.2022.2136969","article-title":"TP53-altered higher-risk myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: A distinct genetic entity with unique unmet needs","volume":"64","author":"Ball","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-023-01882-4","article-title":"Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1","volume":"37","author":"Mill","year":"2023","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"Dohner","year":"2020","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition","volume":"13","author":"Perner","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Fleischmann, M., Bechwar, J., Voigtl\u00e4nder, D., Fischer, M., Schnetzke, U., Hochhaus, A., and Scholl, S. (2024). Synergistic effects of the RARalpha agonist tamibarotene and the Menin inhibitor revumenib in acute myeloid leukemia cells with KMT2A rearrangement or NPM1 mutation. Cancers, 16.","DOI":"10.3390\/cancers16071311"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41409-025-02576-4","article-title":"Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A survey on behalf of the EBMT acute leukemia working party","volume":"60","author":"Dalle","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Marconi, G., Rondoni, M., Zannetti, B.A., Zacheo, I., Nappi, D., Mattei, A., Rocchi, S., and Lanza, F. (2024). Novel insights and therapeutic approaches in secondary AML. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1400461"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","article-title":"CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","volume":"205","author":"Mehta","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e35618","DOI":"10.1002\/cncr.35618","article-title":"A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX","volume":"131","author":"Bergua","year":"2025","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: Post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA overexpression with tamibarotene, a potent and selective RARalpha agonist, is a novel approach in AML","volume":"7","author":"Cluzeau","year":"2023","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"DeZern, A.E., Thepot, S., De Botton, S., Patriarca, A., Deeren, D., Torregrose Diaz, J.M., Marconi, G., Bernal Del Castillo, T., Bergua Burgues, J.M., and Xicoy, B. (2025). Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS. Blood Adv., Online ahead of print.","DOI":"10.1182\/bloodadvances.2025016229"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon, T., Siriwannangkul, T., Kungwankiattichai, S., Leelakanok, N., Rotchanapanya, W., Vittayawacharin, P., Mekrakseree, B., Kulchutisin, K., and Owattanapanich, W. (2022). Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14215239"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: Biology and treatment","volume":"2006","author":"Small","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Capria, S., Trisolini, S.M., Torrieri, L., Amabile, E., Marsili, G., Piciocchi, A., Barberi, W., Iori, A.P., Diverio, D., and Carmini, D. (2024). Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years. Cancers, 16.","DOI":"10.3390\/cancers16162864"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.22.02721","article-title":"Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML","volume":"41","author":"Pratz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1515\/jtim-2025-0028","article-title":"Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation","volume":"13","author":"Fan","year":"2025","journal-title":"J. Transl. Intern. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2387\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:07Z","timestamp":1760033527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":73,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17142387"],"URL":"https:\/\/doi.org\/10.3390\/cancers17142387","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}